A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia

Japanese Journal of Clinical Oncology

Volumn 39, Issue 7, 2009, Pages 425-430

  Yamamoto, Nobuyuki ^a   Sekine, Ikuo ^b   Nakagawa, Kazuhiko ^c   Takada, Minoru ^d   Fukuoka, Masahiro ^c   Tanigawara, Yusuke ^e   Saijo, Nagahiro ^f  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Neutropenia; Pegfilgrastim; Pharmacokinetics; Subcutaneous

Indexed keywords

AMRUBICIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; KRN 125; MITOMYCIN; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VINDESINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NUTRITIONAL DISORDER; PHARYNGITIS; PILOT STUDY; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FILGRASTIM; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649986379     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp038     Document Type: Article

References (10)

1. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3538-85.
2. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
3. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-28.
4. Holms FA, Johnes SE, O'Shaughnessy J, Vukelja S, George T, Savin M, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9.
5. Holms FA, O'Shaughnessy J, Vukelja S, Jones SE, Shogan J, Savin M, et al. Blinded randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31.
6. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
7. Vose JM, Crump H, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-9.
8. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1503-8.
9. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391-8.
10. Roskos LK, Yank B, Schwab G, Lockbaum P, Molineux G, Johnston E, et al. A cytokinetic model of r-metHUG-CSF-SD/01 mediated granulopoiesis and 'self-regulation' of SD-01, elimination in non-small cell lung cancer patients. Blood 1998;92:507a (abstr 2085).